Viewing Study NCT01752920

Bugs

Ignite Creation Date: 2025-12-25 @ 4:19 AM

Ignite Modification Date: 2026-01-22 @ 7:57 PM

Study NCT ID: NCT01752920

Status: COMPLETED

Last Update Posted: 2023-06-05

First Post: 2012-12-14

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Sponsor: Basilea Pharmaceutica

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions:

Condition Brief	Condition Text	View

None	Solid Tumor	View

Keywords:

Keyword Brief	Keyword Text	View

None	FGFR	View
None	ARQ 087	View
None	Targeted therapy	View
None	Molecular therapy	View
None	Tyrosine kinase inhibitor	View
None	TKI	View
None	Receptor tyrosine kinase	View
None	RTK	View
None	Biomarker	View
None	Phase 1	View
None	Phase I	View
None	Solid tumor	View
None	Liver Cancer	View
None	Hepatobiliary carcinoma	View
None	Biliary tract cancer	View
None	Cholangiocarcinoma	View
None	Intrahepatic cholangiocarcinoma	View
None	FGFR inhibitor	View
None	Targeted FGFR kinase inhibitor	View
None	Pan-FGFR inhibitor	View
None	Selective FGFR inhibitor	View
None	FGFR pathway	View
None	FGFR signaling	View
None	Fibroblast growth factor	View
None	FGFR1	View
None	FGFR2	View
None	FGFR3	View
None	FGFR4	View
None	FGF	View
None	FGF19	View
None	FGF21	View
None	FGF23	View
None	FGFR mutation	View
None	FGFR gene fusion	View
None	FGFR gene translocation	View
None	FGFR genetic aberration	View
None	FGFR2 fusion	View
None	FGFR2 translocation	View
None	Phase 1 Clinical Trial	View
None	Phase I Clinical Trial	View
None	Clinical oncology	View
None	Tumor	View
None	Tumour	View
None	derazantinib	View
None	MK-2921	View